Poster for European Congress of Clinical Microbiology and Infectious Diseases 2023

April 15, 2023

The SAIVE Trial, Post-Exposure use of ivermectin in Covid-19 prevention: Efficacy and Safety Results

Ivermectin (IVM) is a well-known drug currently used to treat several parasitic diseases. It has a proven safety profile over many decades of exposure. It is one of the several drugs explored for its potential therapeutic and preventive role against SARS-CoV-2 infection as previous studies had reported its antiviral effects on both RNA and DNA viruses1,2. Caly et al. demonstrated that a single dose of IVM could control the in vitro replication of SARS-CoV-23. Several mechanisms of action have been suggested for its effect on SARS-CoV-24. Those mechanisms could lead to an efficient SARS-CoV-2 prevention, independently of virus mutations5. Post-exposure prophylaxis (PEP) is a method of preventing SARS-CoV-2 infection after a known exposure to the virus that may limit the spread of infection.

Download Poster

Session en français

Rendez-vous le mardi 12 septembre à 18h00 pour la diffusion en direct de l'Assemblée Générale mixte

English session

On Tuesday September 12 at 6:00 p.m. live of the Combined General Meeting (in French)

Êtes-vous un actionnaire de MedinCell ? / Are you a MedinCell shareholder?
Vous êtes / You are :
This field is for validation purposes and should be left unchanged.


  • This field is for validation purposes and should be left unchanged.